SPDR S&P Retail ETF (XRT)
- Previous Close
72.21 - Open
72.26 - Bid 72.99 x 1400
- Ask 73.34 x 3200
- Day's Range
72.23 - 73.49 - 52 Week Range
56.20 - 79.12 - Volume
6,749,626 - Avg. Volume
6,540,604 - Net Assets 509.47M
- NAV 73.29
- PE Ratio (TTM) 12.99
- Yield 1.21%
- YTD Daily Total Return 1.45%
- Beta (5Y Monthly) 1.32
- Expense Ratio (net) 0.35%
In seeking to track the performance of the S&P Retail Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the retail segment of the S&P Total Market Index ("S&P TMI").
SPDR State Street Global Advisors
Fund Family
Consumer Cyclical
Fund Category
509.47M
Net Assets
2006-06-19
Inception Date
Performance Overview: XRT
Trailing returns as of 4/26/2024. Category is Consumer Cyclical.
People Also Watch
Holdings: XRT
Top 10 Holdings (16.03% of Total Assets)
Sector Weightings
Recent News: XRT
Research Reports: XRT
Analyst Report: Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice TargetMOS: What does Argus have to say about MOS?
MOSAIC CO/THE has an Investment Rating of HOLD; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetMOS: Raising target price to $34.00
MOSAIC CO/THE has an Investment Rating of HOLD; a target price of $34.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetMOS: Lowering target price to $32.00
MOSAIC CO/THE has an Investment Rating of HOLD; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target